Abstract
Background Access to contraception is crucial for preventing unintended pregnancies and promoting reproductive rights. In Bangladesh, the contraceptive prevalence rate (CPR) has increased over the decades. However, domestic violence (DV) remains a major concern. Women who experience DV are more likely to have unintended pregnancies and abortions. They are also more likely to live in poverty and experience depression and anxiety.
Objective This study aimed to assess the relationship between contraceptive use and women’s tolerance of DV in Bangladesh.
Methods Data from the Bangladesh Multiple Indicator Cluster Survey (MICS) 2019 was used for the study. The sample size was 47,692 women aged 15-49; data were analyzed using Jamovi software (version 2.3.26). Ethical considerations were strictly followed. Results
The study found a contraception utilization rate of 66.5% among Bangladeshi women of reproductive age. Factors associated with contraceptive use included age, residence, education level of the woman, marital structure, wealth index, and tolerance for domestic violence. Women with high tolerance towards domestic violence had higher odds (AOR: 1.1; 95% CI: 1.017-1.189; p = 0.017) of using contraception than women with no tolerance.
Conclusion The study’s result suggest a complex relationship between contraceptive use, women’s tolerance of domestic violence, and other factors such as age, education, wealth, location, etc. Programs and policies are needed to promote contraceptive use in Bangladesh. Efforts should target socioeconomic, cultural, and psychological factors and barriers which are faced by women exposed to domestic violence. By tackling these challenges, programs, and policies can effectively promote contraception use and improve women’s reproductive health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data will be shared by first author upon reasonable request.
